Vanda Pharmaceuticals targets $1B revenue by 2030 with expanded psychiatry portfolio
Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...
Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year
Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...
The American Journal of Managed Care1d
Oral Roflumilast Shows Promise for Moderate to Severe Psoriasis
Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.
The American Journal of Managed Care2d
Deucravacitinib Shows Long-Term Safety, Efficacy in Psoriasis Trial
A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.
Rosnilimab shows promise in rheumatoid arthritis trial
SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...
How Do You Know It’s Psoriasis? Here Are The Signs And Symptoms You Should Look For
More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...